StimCell Energetics Inc (OTC: STME) is a pre-revenue medical device company developing the eBalance Technology platform, a bioelectric therapy device targeting metabolic conditions including Type 1 and Type 2 diabetes. The company has generated no material revenue from product sales as of its fiscal year ended May 31, 2025, following the suspension of all revenue-generating activities after Health Canada cancelled its Class II Medical Device Licenses for the eBalance Home System and eBalance Pro System due to lapsed MDSAP audits. The company previously held Health Canada Class II Medical Device License #104925 for the eBalance Home System and License #105044 for the eBalance Pro System, both issued in 2020 and both subsequently cancelled. A 510(k) FDA clearance application was withdrawn due to financing constraints. The company reported net cash used in operating activities of $141,600 for the year ended May 31, 2025, carries a stockholders' deficit, and its auditors have issued a going concern qualification. As of August 29, 2025, the company had approximately 74 holders of record. Shares trade on the OTC Markets OTCID platform. David Jeffs serves as Principal Executive Officer and Yanika Silina as Chief Financial Officer.

Revenue model

No active revenue as of fiscal year ended May 31, 2025. Prior revenue model included direct sales of the eBalance Home and Pro Systems and monthly recurring revenue from online sales of eBalance treatment packages, both suspended following cancellation of Health Canada medical device licenses.

Products and services

eBalance Technology: a bioelectric therapy platform. eBalance Home System (former Health Canada License #104925, issued July 17, 2020, cancelled). eBalance Pro System (former Health Canada License #105044, issued August 18, 2020, cancelled). Clinical study data showed systolic blood pressure decline of 9.6% (142 to 128 mmHg) and diastolic decline of 10.4% (78 to 70 mmHg) after seven weeks of treatment in a Health Canada-approved observational trial.

Customers and end markets

Target end market is patients with Type 1 and Type 2 diabetes and related comorbidities including hypertension and peripheral neuropathy. No active commercial customers as of fiscal year ended May 31, 2025.

Value-chain role

Device developer and would-be direct seller of bioelectric therapy hardware and treatment packages. Dependent on regulatory clearance (Health Canada, FDA 510k) before commercial operations can resume. Relies on third-party auditors for MDSAP compliance and transfer agent Pacific Stock Transfer Company for shareholder recordkeeping.

Geographic exposure

Canada-focused regulatory history. U.S. FDA clearance not obtained. No active commercial operations in any geography as of fiscal year ended May 31, 2025.

Source: SEC 10-K, filed 2025-09-02

Industry: Surgical & Medical Instruments & Apparatus Peers: Abbott Laboratories SINTX Technologies Inc MICRON SOLUTIONS INC /DE/ Avinger Inc Dynatronics Corp Motus GI Holdings, Inc. LogicMark Inc Vyome Holdings Inc VIVEVE MEDICAL, INC. Catheter Precision Inc